Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.scr.2020.102066 http://scihub22266oqcxt.onion/10.1016/j.scr.2020.102066 33242791!7585498!33242791     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Stem+Cell+Res 2020 ; 49 (ä): 102066 Nephropedia Template TP {{tp|p=33242791|t=2020. A safety consideration of mesenchymal stem cell therapy on COVID-19 |pdf=|usr=}}{{33242791}} gab.com Text A safety consideration of mesenchymal stem cell therapy on COVID-19 JO: Stem Cell Res http://www.kidney.de/pget.php?&tw=1&pmid=33242791 #FOAvip Due to the multi-potential differentiation and immunomodulatory function, mesenchymal stem cells (MSCs) have been widely used in the therapy of chronic and autoimmune diseases. Recently, the novel coronavirus disease 2019 (COVID-19) has grown to be a global public health emergency but no effective drug is available to date. Several studies investigated MSCs therapy for COVID-19 patients. However, it remains unclear whether MSCs could be the host cells of SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) and whether they might affect the SARS-CoV-2 entry into other cells. Here, we report that human MSCs barely express ACE2 and TMPRSS2, two receptors required for the virus endocytosis, indicating that MSCs are free from SARS-CoV-2 infection. Furthermore, we observed that MSCs were unable to induce the expression of ACE2 and TMPRSS2 in epithelial cells and macrophages. Importantly, under different inflammatory challenge conditions, implanted human MSCs failed to up-regulate the expression of ACE2 and TMPRSS2 in the lung tissues of mice. Intriguingly, we showed that a SARS-CoV-2 pseudovirus failed to infect MSCs and co-cultured MSCs did not increase the risk of SARS-CoV-2 pseudovirus infection in epithelial cells. All these results suggest that human MSCs have no risk of assisting SARS-CoV-2 infection and the use of MSCs as the therapy for COVID-19 patients is feasible and safe. Twit Text FOAVip A safety consideration of mesenchymal stem cell therapy on COVID-19 ????Stem Cell Res http://www.kidney.de/pget.php?&tw=1&pmid=33242791 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33242791 #FOAvip English Wikipedia <ref>{{Cite pmid|33242791}}</ref> A safety consideration of mesenchymal stem cell therapy on COVID-19 #MMPMID33242791 Cao Y; Wu H; Zhai W; Wang Y; Li M; Li M; Yang L; Tian Y; Song Y; Li J; Wang Y; Ding Q; Zhang L; Cai M; Chang Z Stem Cell Res 2020[Dec]; 49 (ä): 102066 PMID33242791show ga Due to the multi-potential differentiation and immunomodulatory function, mesenchymal stem cells (MSCs) have been widely used in the therapy of chronic and autoimmune diseases. Recently, the novel coronavirus disease 2019 (COVID-19) has grown to be a global public health emergency but no effective drug is available to date. Several studies investigated MSCs therapy for COVID-19 patients. However, it remains unclear whether MSCs could be the host cells of SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) and whether they might affect the SARS-CoV-2 entry into other cells. Here, we report that human MSCs barely express ACE2 and TMPRSS2, two receptors required for the virus endocytosis, indicating that MSCs are free from SARS-CoV-2 infection. Furthermore, we observed that MSCs were unable to induce the expression of ACE2 and TMPRSS2 in epithelial cells and macrophages. Importantly, under different inflammatory challenge conditions, implanted human MSCs failed to up-regulate the expression of ACE2 and TMPRSS2 in the lung tissues of mice. Intriguingly, we showed that a SARS-CoV-2 pseudovirus failed to infect MSCs and co-cultured MSCs did not increase the risk of SARS-CoV-2 pseudovirus infection in epithelial cells. All these results suggest that human MSCs have no risk of assisting SARS-CoV-2 infection and the use of MSCs as the therapy for COVID-19 patients is feasible and safe. |*Mesenchymal Stem Cell Transplantation[MESH] |*Mesenchymal Stem Cells/metabolism/pathology/virology[MESH] |*Safety[MESH] |Angiotensin-Converting Enzyme 2/biosynthesis[MESH] |Animals[MESH] |COVID-19/*transmission[MESH] |Cell Line[MESH] |Heterografts[MESH] |Humans[MESH] |Male[MESH] |Mice[MESH] |SARS-CoV-2/*metabolism[MESH]A safety consideration of mesenchymal stem cell therapy on COVID-19 (epmc).pdf DeepDyve Pubget Overpricing